Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | The use of miRNAs as predictive biomarkers in CML

Andrew Wu • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Andrew Wu, BS, MS, British Columbia Cancer Agency, Vancouver, Canada, comments on the use of microRNAs (miRNAs) as predictive biomarkers at diagnosis and post-treatment in chronic myeloid leukemia (CML), highlighting the challenges associated with using miRNAs as biomarkers. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrew Wu

1:11
Gene knockdown strategies to investigate the properties of leukemic stem cells
Andrew Wu • 22 Oct 2022
1:06
The potential of targeting PAK6 in CML
Andrew Wu • 22 Oct 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals